Source-linked briefs built from xcircl's own datasets. We publish what we can substantiate — and label what's still in progress.
The U.S. GLP-1 market moved from prescription-gated to direct-to-consumer in under two years. Demand for semaglutide- and tirzepatide-based treatments outran the infrastructure consumers rely on to compare providers — leaving buyers to navigate daily-changing prices, shifting telehealth rules, and wide variance in provider quality with no neutral reference point.
xcircl tracks 6,028 GLP-1 clinics across 558 U.S. cities in all 50 states and DC, refreshed daily. For each clinic we capture published pricing and a set of source-linked verification signals:
Pricing is tracked across seven brands and formulations: Wegovy, Zepbound, Ozempic, Mounjaro, Wegovy Oral, Rybelsus, and compounded semaglutide. Sources are Google Maps, the NPI Registry, LegitScript, and the FDA.
In a market where the same molecule can be priced very differently from one provider to the next, the presence or absence of a published price is itself a meaningful signal. A clinic that publishes pricing is making a comparable, accountable claim; one that doesn't requires a consultation before a buyer learns the cost. Pairing published price with independent verification — does the provider hold LegitScript certification, does the prescribing physician match the NPI registry, is there an FDA flag — separates transparent, compliant providers from the rest.
The figures above are drawn directly from the live dataset and are stated as counts we can substantiate. Quantified findings — the share of clinics publishing prices, price dispersion by brand and metro, and the correlation between transparency and verification — depend on field-level measurement we are still formalizing. We would rather publish the coverage and method now and release quantified results when they meet our bar than lead with numbers we can't stand behind. Geocoding is also still in progress: roughly 1,000 of 6,028 clinics are fully geocoded today.
The dataset behind this brief is available for licensing and enrichment. See the GLP-1 Clinic Intelligence dataset or request a sample.
This brief is informational and is not medical advice. See our Terms.
Provider density and category mix across 5,500+ U.S. cities, drawn from the Pet Care Provider dataset.
Publishing 2026How provider supply concentrates and thins across states and metros — once geocoding coverage is complete.
Publishing 2026Want a custom analysis of a local-service market? Discuss a data partnership →